ITINSIGHTS & RESEARCH NOTES
Useful thinking before expensive decisions.
Short research and strategy notes from the ExaMedix approach: evaluate evidence, make assumptions explicit and design experiments that can change a decision. These are independent perspectives, not peer-reviewed clinical publications.
RESEARCH NOTE 01
Assess healthcare AI beyond the demonstration
A fluent interface or impressive example does not show how a system performs under operational constraints. Evaluation should begin with the decision it supports, the population or workflow in scope, the consequences of error and the evidence needed to justify adoption.
A practical assessment separates model capability from workflow reliability. It tests failure modes, integration effort, monitoring, cost, human oversight, privacy and relevant regulation. The output is a bounded recommendation, including situations where deployment should not proceed.
Question
Which measurable problem is the system supposed to improve?
Evidence
Does validation match the intended users, setting and error consequences?
Decision
What result is strong enough to justify a pilot, and what stops it?
RESEARCH NOTE 02
Why an innovation project needs a stop rule
Early exploration has value when it reduces uncertainty. Projects become expensive when their success criteria are continually rewritten to explain away weak evidence. Before testing, define the smallest result that would change the next investment decision.
A useful project charter names its hypothesis, baseline, test data, dependencies, acceptable risks, costs and stop conditions. This makes a negative result useful: a disciplined decision not to scale is still a result.
NOW
Evidence and operational fit justify action within defined constraints.
NEXT or WATCH
Potential is credible, but dependencies or evidence remain incomplete.
FRONTIER or LOW PRIORITY
Exploratory relevance or insufficient current strategic value.
RESEARCH NOTE 03
Reproducibility before claims in rare-disease research
Computational evidence synthesis can help organize biological mechanisms, disease context and candidate intervention hypotheses. It cannot substitute for clinical validation. A research workflow should preserve input provenance, versioned assumptions, exclusion reasons and the exact steps required to reproduce an output.
For Rare Disease MVA Pharma, the distinction matters: a ranked candidate is a research hypothesis, not an approved or effective treatment. Results are meaningful only with explicit limitations, independent verification and clinical interpretation by qualified specialists where appropriate.
Next conversation